statistiche ricercatore

Continente	#
EU - Europa	26.358
NA - Nord America	921
AS - Asia	489
SA - Sud America	56
Continente sconosciuto - Info sul continente non disponibili	47
AF - Africa	13
OC - Oceania	4
Totale	27.888

Nazione	#
IT - Italia	26.056
US - Stati Uniti d'America	896
CN - Cina	187
SG - Singapore	157
SE - Svezia	74
DE - Germania	73
VN - Vietnam	63
BR - Brasile	45
UA - Ucraina	45
GB - Regno Unito	29
FI - Finlandia	27
FR - Francia	22
CA - Canada	14
BD - Bangladesh	12
IN - India	12
HK - Hong Kong	10
IQ - Iraq	9
PK - Pakistan	8
KR - Corea	7
MX - Messico	5
AU - Australia	4
BE - Belgio	4
ES - Italia	4
ID - Indonesia	4
JP - Giappone	4
NL - Olanda	4
SA - Arabia Saudita	4
AR - Argentina	3
JM - Giamaica	3
KE - Kenya	3
PL - Polonia	3
RO - Romania	3
RU - Federazione Russa	3
VE - Venezuela	3
ZA - Sudafrica	3
AT - Austria	2
AZ - Azerbaigian	2
CO - Colombia	2
DZ - Algeria	2
EC - Ecuador	2
LA - Repubblica Popolare Democratica del Laos	2
MA - Marocco	2
RS - Serbia	2
TR - Turchia	2
AL - Albania	1
CH - Svizzera	1
CR - Costa Rica	1
EG - Egitto	1
GR - Grecia	1
IL - Israele	1
JO - Giordania	1
LB - Libano	1
LK - Sri Lanka	1
LT - Lituania	1
LY - Libia	1
MK - Macedonia	1
NO - Norvegia	1
PA - Panama	1
PH - Filippine	1
PY - Paraguay	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
Totale	27.841

Nome	#
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis	4.574
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ?	3.144
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis	2.834
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients	2.729
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA	2.603
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis	2.553
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI	2.445
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma	2.419
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C	2.172
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis	1.921
HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution	494
Totale	27.888

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	1.094	0	121	41	117	126	85	63	53	166	123	109	90
2022/2023	1.537	113	240	264	123	133	97	55	106	97	114	122	73
2023/2024	1.661	65	207	74	152	143	237	221	103	89	84	150	136
2024/2025	1.772	216	327	283	280	161	167	192	15	38	32	27	34
2025/2026	843	86	38	52	52	71	69	188	50	64	113	51	9
2026/2027	12	9	3	0	0	0	0	0	0	0	0	0	0
Totale													27.888

UNICA IRIS Institutional Research Information System